Clinical trials

This research study is testing an experimental vaccine that can potentially prevent COVID-19 disease. This experimental vaccine is called RVM-V001. This research study aims to look at the safety and immune responses of RVM-V001. You are invited as a possible participant in this study if you are of good health, have been previously vaccinated for COVID-19, and have not contracted the COVID-19 infection in the last 6 months prior to enrolment.  Who Can Participate?

• Male and female healthy volunteers
• Is age ≥18 and ≤ 65 years on Study Day 1
• Have completed either a 2-dose primary vaccination series with Pfizer or Moderna, OR have completed the primary series and one homologous booster of Pfizer or Moderna; the last dose in all cases should have been administered at least 6 months prior to enrolment.
• Body mass index of 18-32 kg/m2, inclusive, at screening.
• Must not have documented history of COVID-19 within 6 months prior to enrolment.
• Must not have RT-PCR test for COVID-19 within 2 days of screening
• Must not have received any COVID-19 vaccine other than Pfizer or Moderna.
• Must not have received more than 3 doses of any mRNA (eg. Moderna) COVID-19 vaccine.
• Must not be pregnant or breastfeeding or intending to become pregnant or father children within the projected duration of the trial.
• Must not have history of infection of Middle East respiratory syndrome (MERS), or Severe Acute respiratory syndrome (SARS).
• Must not have positive serology test results for hepatitis C virus antibody, HIV antibody, hepatitis B virus surface antigen at Screening.

This study will be investigating whether a treatment called Tozorakimab could help manage COPD exacerbations (often called flare-ups, where COPD symptoms get worse) in patients who are currently receiving treatment for COPD. If successful, the findings from this will help in the development of future treatments for individuals with COPD  – now recruiting If you:

• Individuals aged 40 and above who have been diagnosed with COPD for at least one year
• Must be a previous or current smoker
• Must have had at least 1 COPD flare-up in the last 12 months
• Must be regularly taking inhaled medication for COPD
• Must not have any other clinically important pulmonary disease other than COPD
• Must not have a current diagnosis of asthma
• Must not have a planned major surgical procedure within the next 16 months
• Must not have had a cancer diagnosis within the last 5 years (some skin cancers and cervical cancers can be included if treated more than 1 year ago) 
• Must not currently require the use of long-term oxygen therapy
• Must not have a history of alcohol or substance abuse disorder
• Must be able to attend 16 study visits at the research site over approximately 62 weeks

Enhance is conducting a research study to evaluate the impact of a nurse practitioner-led memory clinic for people living with dementia and their carer/ families.

The research will be conducted over a 12-month period and participants will be asked to complete a clinical interview every 3-months. These clinical interviews will go for about 90 minutes. The clinical interviews will include questions about cognition, daily function, quality of life, mental wellbeing.

The outcomes of this research will be used to improve services and resources for people living with dementia and their carer/ families. The findings will be presented in journals and at conferences so healthcare professionals can learn from this project.

Please register your interest in taking part via email or phone:

Amy Montgomery

Nurse Practitioner/ Lecturer

E: enhance@ihmri.org.au

T: 0456 845 196